A roundup of exits, including IPOs and acquisitions, across the tech transfer ecosystem.

Syndesi Therapeutics, a Belgium-based developer of therapies to treat cognitive impairment, was acquired by pharmaceutical firm AbbVie yesterday for $130m upfront, with the potential for up to $870m in milestones. The agreement provided an exit to Vives Louvain Technology Fund, the university venture fund of Université Catholique de Louvain, and V-Bio Ventures, the venture capital firm linked to research institute VIB. Syndesi last raised $21m in a series A round backed by the two aforementioned investors in February…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).